Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedAdded a consolidated Locations section listing participating sites across Alabama, Arizona, California, Illinois, Indiana, Kansas, Michigan, Missouri, Ohio, Tennessee, and Utah, and removed prior state-location headings. The HHS Vulnerability Disclosure link was removed and the revision updated to v3.3.3.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe Study Record Dates section now displays Last Update Posted (Estimated) and a new Revision: v3.3.2 label, while the previous labels Last Update Posted and Revision: v3.2.0 were removed.SummaryDifference0.1%

- Check40 days agoChange DetectedMinor maintenance updates were made: upcoming dates were added (2025-11 and 2026-11-04) and a government funding lapse notice was removed. These changes do not affect the study details, eligibility criteria, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check62 days agoChange DetectedNo substantive changes to the study details; the screenshots show only minor layout/formatting adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check83 days agoChange Detected- Added a government-operation notice and status links, clarifying potential delays and current NIH Clinical Center openness. - Removed the previous version tag (v3.1.0) and introduced v3.2.0.SummaryDifference2%

- Check91 days agoChange DetectedPage updated from v3.0.2 to v3.1.0; a specific term (Melanoma, Cutaneous Malignant) was removed. If core content and essentials are unchanged, this is a minor revision update with terminology pruning.SummaryDifference0.1%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.